GLP-1 Drugs Linked to GI Effects, Uncertain Signals

Umbrella review evaluates over 1,700 trials to assess noncardiometabolic outcomes beyond weight and glycemic effects.

1

GLP-1 receptor agonists are linked to increased gastrointestinal adverse events, with high odds for nausea, vomiting, and diarrhea.
2

Evidence suggests GLP-1 RAs may lower the odds of serious infections and respiratory disease, but findings are of low to moderate certainty.
3

Associations with other health outcomes, including fractures and dementia, did not meet high-credibility thresholds and remain exploratory.
4

Methodological concerns were noted, including lack of prespecified protocols and inconsistent definitions in adverse event reporting.
5

Current evidence on GLP-1 RAs is insufficient for definitive conclusions, highlighting the need for further research.

1